This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NeuBase Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Todd Branning

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.4yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Todd Branning'un ücretlendirmesi NeuBase Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-US$25m
Dec 31 2022	n/a	n/a	-US$30m
Sep 30 2022	US$922k	US$311k	-US$34m

Tazminat ve Piyasa: Todd şirketinin toplam tazminatının German pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Todd şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Todd Branning (54 yo)

2.4yrs

Görev süresi

US$922,445

Tazminat

Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dietrich Stephan	Founder	4.9yrs	US$1.15m	6.14% € 78.5k
Dov Goldstein	Independent Chairperson	4.9yrs	US$74.42k	0.040% € 510.9
Eric Richman	Independent Director	4.9yrs	US$68.38k	0.060% € 765.3
George Church	Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board	1.1yrs	Veri yok	Veri yok
Steven Dowdy	Member of Gene Editing & Scientific Advisory Board	4.7yrs	Veri yok	Veri yok
James Coull	Member of Gene Editing Advisory Board	1.1yrs	Veri yok	Veri yok
Randy Davis	Member of Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Danith Ly	Member of Advisory Board	no data	Veri yok	Veri yok
Robert Friedlander	Chair of Scientific Advisory Board	no data	Veri yok	Veri yok
Peter Nielsen	Member of Gene Editing & Scientific Advisory Board	3.7yrs	Veri yok	Veri yok
Eriks Rozners	Member of Gene Editing & Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Gerald Mcdougall	Independent Director	3.1yrs	US$59.79k	0% € 0

3.6yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: O7P 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

This company listing is no longer active

NeuBase Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

NeuBase Therapeutics, Inc. Announces CEO Changes

NeuBase Therapeutics, Inc. Announces CEO Changes

Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 28, 2023

High number of new and inexperienced directors

NeuBase Therapeutics, Inc. Announces Resignation of Eric J. Ende as Board of Director

Recent updates

NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from S&P TMI Index

New major risk - Financial data availability

The Nasdaq Stock Market LLC Notifies NeuBase Therapeutics Regarding Non-Compliance with the Minimum Bid Price Requirement and Ineligible for a Second 180 Calendar Day Period to Regain Compliance

NeuBase Therapeutics, Inc. Announces CEO Changes

NeuBase Therapeutics, Inc. Announces CEO Changes

New minor risk - Financial data availability

NeuBase Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away

New major risk - Shareholder dilution

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 28, 2023

High number of new and inexperienced directors

NeuBase Therapeutics, Inc. announced that it has received $3.512751 million in funding

NeuBase Therapeutics, Inc. Presents Non-Human Primate Data Illustrating Stealth Editors Are Non-Immunogenic, Opening the Door to Redosing

Neubase Therapeutics, Inc. Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors

NeuBase Therapeutics, Inc. Announces Resignation of Eric J. Ende as Board of Director

NeuBase Therapeutics, Inc. Announces Formation of Gene Editing Advisory Board

NeuBase Therapeutics, Inc. Announces Resignation of William Mann as President and Chief Operating Officer, Effective October 31, 2022

NeuBase Therapeutics, Inc. to Reduces its Workforce by Approximately 60%

NeuBase Therapeutics, Inc. Announces Executive Changes

NeuBase Therapeutics Receives Non-Compliance Letter from Nasdaq

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 08, 2022

NeuBase Therapeutics, Inc. Announces Promotion of William Mann to President

NeuBase Therapeutics, Inc. Presents New Preclinical Data At ASGCT 2022 for Its Dm1 Program Demonstrating Wide Tissue Distribution and Supporting Differentiated Whole-Body Treatment Solution

High number of new and inexperienced directors

CFO, Treasurer & Secretary Samuel Backenroth has left the company

NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from Russell 3000E Index

NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth

Independent Director has left the company

New 90-day high: €8.75

New 90-day high: €8.05

New 90-day low: €5.90

NeuBase Therapeutics Announces Positive Preclinical in Vivo Data for Patrol Enabled Anti-Gene for the Treatment of Myotonic Dystrophy Type 1

NeuBase Therapeutics Announces Appointment of Curt Bradshaw as Chief Scientific Officer

NeuBase Therapeutics Announces Addition of Eriks Rozners and Randy Davis to Scientific Advisory Board

NeuBase Therapeutics, Inc. Announces Addition of Peter Nielsen, Ph.D., Inventor of Peptide Nucleic Acid Technology, to Scientific Advisory Board

NeuBase Therapeutics, Inc. Enters into Lease Agreement with 350 Technology Drive Partners, LLC

New 90-day low - €6.30

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş